Complix Receives EUR1.9 Million IWT Grant to Accelerate Development Of Alphabodies(TM) against Intracellular Disease Targets, Including Cancer
HASSELT, Belgium, October 30, 2012 /PRNewswire/ –
Complix announces that it has been awarded a EUR1.9 million grant (approximately
USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by
Science and Technology in Flanders). The grant will allow Complix to accelerate the
development of its unique cell penetrating Alphabodies (CPABs), against a range of
intracellular disease targets, including cancer.
Alphabodies represent a novel therapeutic development platform with the potential to
address a vast number of disease targets that are currently considered “undruggable” by
the two main classes of therapeutic drugs: small chemical drugs and therapeutic
antibodies. In particular their ability to act on intracellular protein targets represents
a major medical and commercial opportunity.
During the past year, Complix has generated a wealth of data demonstrating the
attractive properties of CPABs that are capable of acting on intracellular disease
targets. These results show that CPABs are taken up effectively by tumor cells. Once
inside cancer cells the CPABs can act on an oncogenic target protein and block its
function, thereby inducing apoptosis (cell death).
Dr Mark Vaeck, CEO of Complix, said: “We are delighted to have received this funding
from IWT, which is a clear endorsement of the power of our unique CPAB platform. The
results that we have generated so far indicate this platform has the potential to
transform the pharmaceutical industry’s ability to address the most interesting class of
potential drug targets, namely intracellular protein-protein interactions (PPIs).
“Although intracellular PPIs are known to be involved in a variety of important
disease processes, such as cancer, autoimmunity, CNS and metabolic diseases, most of them
have been found intractable by small chemicals or antibodies. Whilst other new technology
platforms are currently also attempting to address this opportunity, we believe that
Complix is well positioned to become a leading player in this next generation of so called
“cross-over therapeutics”, which have the potential to boost future R&D pipelines and
revitalize the growth of the pharmaceutical industry.”
Alphabodies are small single chain alpha-helical proteins that are designed by
computer modeling, but are inspired by naturally existing polypeptide structures.
Alphabodies can address a diverse range of traditionally undruggable disease targets and
combine the best beneficial properties of biologics and small chemical drugs, such as high
specificity and potency on large protein targets, with efficient intracellular penetration
and excellent stability in human serum.
Alphabodies also have the potential to be applied in other fields beyond the treatment
of human disease. Complix recently announced an important value-generating partnership
with Monsanto Company that will apply Complix’ Alphabodies to create novel products for
Complix discovers and develops Alphabodies, a novel and proprietary class of
biopharmaceuticals that delivers significant advantages over current protein therapeutic
approaches. Alphabodies’ most important advantage is their ability to address currently
undruggable extracellular and, in particular, intracellular targets.
Complix is developing cell penetrating Alphabodies (CPABs) that have the potential to
modulate intracellular PPIs, and has generated data demonstrating that CPABs are able to
enter cells, bind to disease targets and can generate biological effects at low
concentrations. CPABs have been designed to tackle the significant proportion of all known
human disease targets that are located inside cells and cannot be addressed by either
small chemical drugs or biologics. These targets belong to the most interesting class of
potential drug targets, namely intracellular protein-protein interactions (PPIs), which
are involved in important disease processes, such as those causing cancer, CNS,
inflammation or metabolic diseases.
Alphabodies are composed of structurally constrained alpha-helical peptide coils,
which make them ideal scaffolds for therapeutic applications as they combine the
specificity of antibodies with small molecule-like properties. Alphabodies’ unique design,
which has been invented by the Complix founders, means that the Company has a unique
freedom-to-operate position. Complix has already established a strong intellectual
property position for its Alphabody platform through the filing of several broad patent
Complix’s current R&D focus is on the development of novel Alphabody-based therapies
for inflammation/autoimmunity and cancer.
Complix raised EUR 7 million through a Series A equity financing round in 2010, with
Vesalius Biocapital, LRM and Credit Agricole Private Equity (currently Omnes Capital) as
the main investors.
Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille,
and has research facilities in Ghent (Belgium) and in Luxembourg. The Company has a fully
owned subsidiary in Luxembourg and a strategic alliance with the public research institute
CRP-Sante. For further information, please visit http://www.complix.com.
Contacts Complix NV Dr. Mark Vaeck, CEO +32-9-261-69-40